

09/424815

PCT/NL98/00311

WO 98/54314

1/17

**PEPTIDE**

**Ubiquicidine:**  
**(59aa, 6.654 kD)**

**(1-18, 2.153 kD) KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRM**

**(29-41, 1.910 kD) TGRAKRRMQYNRR**

**(18-29, 1.643 kD) KVAKQEKKKKKT**

**(18-35, 3.477 kD) KVAKQEKKKKKTGRAKRR**

**(18-35, 3.656 kD) AKVAKQEKKKKKTGRAKRR**

**(29-35, 953 D) TGRAKRR**

**(42-59, 2.213 kD) FVNVVPTFGKKKGPNANS**

**(36-41, 957 D) MQYNRR**

**FIG.**

2/17




FIG. 2A

3/17




FIG. 2B

4/17

Effect of ubi (18-35) on herpes simplex virus




FIG. 3

5/17

Effect of ubi(18-35) on *Mycobacterium fortuitum*




FIG. 4

6/17

Effect of ubi (18-35) and control peptides on *S. aureus*  
and antibiotic -resistant *S. aureus* (MRSA )





FIG. 5

7/17



8/17




FIG. 7

9/17

Effect of ubi (18-35) and D-al<sub>a</sub>-protected ubi (18-35) on *S. aureus* and antibiotic-resistant *S. aureus* (MRSA)





FIG. 8

10/17



11/17




FIG. 10

09/424815

PCT/NL98/00311

WO 98/54314

12/17

Accumulation of  $^{99m}$ Tc-labelled ubiquicidin (18-35) in the thigh muscle infected by *staphylococcus aureus* ATCC 25923 after intraperitoneal injection






FIG. 11

13/17

Accumulation of  $^{99m}$ Tc-labelled peptides in the thigh muscle infected by Klebsiella pneumoniae ATCC 43816

FIG. 12

Accumulation of  $^{99m}$ Tc-labelled ubiquicidine 18-35 in an infection but not in inflammations

15/17




FIG. 14 A

16/17

Effect of antimicrobial peptides on an experimental Klebsiella pneumoniae infection






FIG. 14B

17/17

## Antimicrobial effect of ubiquidine 29-41 and 18-35 and defensin-1 in mice



## Antimicrobial effect of ubiquidine 29-41 and 18-35 and defensin-1 in mice treated with cyclofosfamide

FIG.15